Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The third-term Democrat touted past achievements and trumpeted a long list of policy initiatives, many of which he previewed in a series of announcements over the past month. Cuomo also stressed the need for fiscal restraint, with the state staring at a $6 billion budget gap, caused largely by soaring Medicaid spending. The agenda Cuomo outlined in the speech includes plans for expanding anti-discrimination protections in the state constitution, an overhaul for New York City's Penn Station and a proposed ban on foam food containers. Cuomo also outlined another ban that would cover marketing flavored e-cigarettes to children, initiatives intended to lower the cost of prescription drugs, guaranteed paid sick leave time for more New York workers and expanded universal pre-kindergarten. "New York at her best is the progressive capitol of the nation, and we must fulfill that destiny again this year," Cuomo said. Cuomo delivered his address at the Empire State Plaza Convention Center in downtown Albany to an audience of members of the Legislature and top politicians from around the state. The speech kicked off a legislative session running through June 2. The governor's address comes after several episodes of violence targeting Jewish people, including an attack by a man who stormed inside the home of a Monsey rabbi, Chaim Rottenberg, and stabbed five people at a Hanukkah celebration. Rottenberg delivered a blessing before Cuomo's address and called for tolerance. "I will never forget the horror of that night," Rottenberg said. "But I will also never forget how we continue to celebrate after that day, how we continue to rejoice in the miracle of Hanukkah. I will never forget the resilience on display that night and in the following days, the resilience of Jewish people and the resilience of New York." Cuomo is proposing a new law targeted at domestic terrorism and said New York would be the first state in the U.S. to enact such legislation. The new law would apply to crimes in which at least one person died and victims were targeted by their race, religion and gender, among other topics. Cuomo called the attack "intolerable" and pledged the state won't stand for it. "They attacked me, and they attacked you," Cuomo said. "These are the times, my friends, when New York state is called upon to lead to set a course for a troubled nation searching its way through the fog of confusion," he said. In a policy briefing book that accompanied his speech, Cuomo said his proposal to legalize marijuana would limit the sale of cannabis products to adults over age 21. But he only briefly mentioned his legalization proposal in his address Wednesday, to tepid applause. A similar proposal to legalize recreational marijuana failed last year among disagreements over funding and hesitation from suburban Democrats. Lawmakers instead scaled back penalties for possession of small amounts of marijuana and created a process for expungement. Cuomo has declared "Making Progress Happen" as his slogan for 2020. But any progress will have to come while the state is grappling with a budget gap fueled by soaring Medicaid costs. Debate over how to handle the shortfall is expected to color virtually every policy debate this year. Hundreds of activists rallied in Albany demanding action on issues including the state's ambitious climate change goals. Cuomo called climate change the "transcendent threat of our times" and proposed sending voters a $3 billion bond in November to fund a flood reduction and habitat restoration program he is calling Restore Mother Nature. "Because no economic strategy, no social justice reform, no education policy will be worth a damn if we don't have a planet to live on," he said. Cuomo has yet to share many details about his plans to address soaring costs of the Medicaid program, which serves over 6 million people. The governor called Wednesday for improved accountability in the Medicaid system, saying safeguards were needed to limit potential overspending on the program by municipalities. More details of how the administration plans to address the funding gap may have to wait for his budget proposal, expected in mid-January. Cuomo has cautioned against overspending while pledging not to raise taxes. That budget-conscious message could clash with more left-leaning lawmakers and advocates who want to balance the budget with new taxes on the wealthy. The governor's party has seen big political wins in recent years, even as some long-time Democratic incumbents have lost to more left-wing challengers. But Cuomo argued Wednesday true progressive politics must be grounded in "reality" and champion results over rhetoric. Republicans, who have seen their clout diminish in Albany, say they will hold down spending and resist new taxes. Republican leaders including state GOP chairman Nick Langworthy criticized the governor for failing to address the budget deficit as well as a mounting debate over bail reforms enacted last year. Cuomo and other Democrats have signaled they are open to making changes to the statute. In his preview announcements over the past month, Cuomo has released proposals to ban untraceable guns, study high speed rail, allow liquor sales in movie theaters, require the use of American-made steel and iron on infrastructure projects and ease rules for prosecuting sexual assault involving intoxicated victims, among other initiatives. Assembly Speaker Carl Heastie, a Democrat, said lawmakers have their own priorities this year, including working to increase school aid, affordable housing, infrastructure, local businesses, rural hospitals and mental healthcare.
[A]: Cuomo's 2020 agenda: Fight hate, help planet, legalize pot.

[Q]: The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it's understandable that they wouldn't comment on it and that's why we're rating this Not Applicable. But let's be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug even one from the FDA will include some mention of cost in its message. This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven't been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent. As noted above, tumor shrinkage doesn't always lead to improvements in survival or quality of life. It is a surrogate endpoint a substitute for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the "Summary," another larger study is underway to assess the drug's impact on extending life and improving quality of life. The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are "immune-mediated." We would have liked a bit more context on what this term means for patients. The release outlines that this is the very first clinical trial of this compound for safety and efficacy, and under which regulatory paths the drug was assessed, including "breakthrough therapy designation, priority review status and accelerated approval." We're giving this release the benefit of the doubt and rating it Satisfactory for its bare bones description of the trial (and since we already addressed the lack of long-term survival data in the "Benefits" section.) As it stands, the results from the small trial were preliminary and short-term and did not reflect long-term survival. We would have liked to see a reference or link to the completed trial where one could look at the results to assess independently or learn more about the outcomes. We think the release should have provided more data on the patient demographics, the treatment regimen (dosing amount and schedule) as well as the range in tumor reduction. There is no disease mongering. This release describes the approval of a new drug by a regulatory agency, but we'd still like to know who sponsored the study that's the basis for the approval. It's not enough to state who markets the drug. The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn't stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn't respond to initially is the usual treatment. The FDA's approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn't state this explicitly but it can be inferred.) A NYT article said the drug would be available in about two months. The release clearly states this product is first of its kind for this type of cancer. We found no unjustifiable language.
[A]: FDA approves new, targeted treatment for bladder cancer

[Q]: Just days after Chinese scientists shared the genetic map of the culprit coronavirus, researchers at the U.S. National Institutes of Health had engineered a possible key ingredient for a vaccine they hope to begin testing by April. Scientists from Australia to France, along with a list of biotech and vaccine companies, jumped in the race, pursuing different types of inoculations. And Texas researchers froze an experimental vaccine developed too late to fight an earlier coronavirus SARS, or severe acute respiratory syndrome but are pushing U.S. and Chinese authorities to give it a try this time around. Because the new virus is a close cousin of SARS, it just might protect, said Dr. Peter Hotez of Baylor College of Medicine and Texas Children's Hospital. All that work is coming at lightning speed compared to past outbreaks. Yet many experts agree it still may take a year if every step along the way goes well for any vaccine to be ready for widespread use. That's if it's even needed by then. Globally, more than 31,400 people are infected and the death toll climbed past 630. The overwhelming majority are in China, but more than 310 people with the illness have been reported in over two dozen other countries. For now, health officials are isolating the sick to fight spread of the virus, which causes fever, cough and in severe cases pneumonia. With no specific treatment, some doctors also are experimenting with antiviral medicines developed for other conditions. "Ours is already manufactured and could take off pretty quickly," said Hotez, who created the earlier SARS vaccine with Texas Children's colleague Maria Elena Bottazzi. But "there's still no road map for what you do to make a vaccine in the midst of a devastating public health outbreak." NIH specialists say rather than chasing outbreaks, it's time to pursue prototype vaccine designs that could work for entire virus families, ready to be pulled off the shelf at the first sign of a new disease. "We have the technology now. It's feasible from an engineering and biological standpoint," said Dr. Barney Graham, deputy director of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center. Without that step, "we're going to be at risk for new pandemics." A FASTER VACCINE RECIPE Traditionally, making vaccines required first growing lots of virus in a lab. The NIH team is pursuing a newer and far faster method: Simply use a piece of the virus' genetic code, called messenger RNA or mRNA, that instructs cells to make a particular protein. "We think of RNA as the software of life," said Dr. Tal Zaks, chief medical officer of Moderna Inc., which is developing mRNA vaccines for other diseases and working with NIH on the new coronavirus. Inject the right piece and "you've taught the body to make its own medicine," he explained. As cells produce just that protein, the immune system learns to recognize it, primed to attack if the entire virus ever comes along. The target: A protein aptly named "spike" that lets the virus bind to cells. It studs the surface of coronaviruses the new one as well as its cousins SARS, which erupted in China in 2002 and spread to 26 countries, and MERS, or Middle East respiratory syndrome, which emerged in 2012. Graham's team zeroed in on the RNA responsible for the new virus' production of spike and then because prior research showed the protein can change shape engineered a more stable version of it. Moderna is manufacturing samples of the synthetic mRNA vaccine for NIH to use in animal studies and, hopefully within three months, first-stage safety tests in people. If further testing proves it really works, the hope is scientists could simply swap in a new spike code if another coronavirus comes along. That's important because after three such outbreaks in less than 20 years, "this is not the last," predicted Dr. Mark Denison, a virologist at Vanderbilt University Medical Center. It's key to find vaccine "strategies that go after these unique things common to every coronavirus." WHAT ELSE IS IN THE PIPELINE Inovio Pharmaceuticals is pursuing a similar approach with synthetic DNA, and recently reported promising results from first-stage testing of a MERS vaccine. It's collaborating with a Chinese company, Beijing Advaccine, in hopes of being able to test a new vaccine candidate in China later this year. In France, researchers at the Pasteur Institute are piggybacking on the tried-and-true vaccine against measles. They've had some early success mixing genetic material from other viruses into that vaccine, and now hope to put the immune system on alert against this new coronavirus in the same way. "The work we're doing now involves making a vaccine against measles but re-engineered in the sense that it has antigens from the new coronavirus," said virologist Frederic Tangy, head of Pasteur's vaccine innovation department. What about Hotez's old SARS vaccine? In that case a piece of the spike protein was genetically engineered and grown in a lab, a classic vaccine technology compared to the newer and less proven Moderna and Inovio approaches. The Texas researchers showed the vaccine protected animals but in 2016 ran out of money for further testing and froze what was left. Every six months, Hotez thaws a small sample to make sure it's still usable. CHASING OUTBREAKS Past outbreaks are full of such missed opportunities: There's no commercial vaccine for MERS even though illnesses still occur. The birth defect-causing Zika outbreak was ending by the time experimental shots were ready to test. The bright spot: Ebola vaccines. Some candidates began early testing during the massive Ebola epidemic in West Africa in 2014-2016, although the outbreak waned before scientists had proof they worked. But authorities and vaccine companies kept up the research, and by 2018 shots were ready to help tamp down an outbreak still smoldering in Congo. The World Health Organization will meet next week to identify promising drug and vaccine candidates for the new coronavirus and fast-track their development, much like happened with Ebola. "To put it bluntly, we're shadow boxing," said WHO Director-General Tedros Adhanom Ghebreyesus. "We need to bring this shadow out into the light so that we can attack it properly." ___ Associated Press writers Rodrique Ngowi in Boston, Alex Turnbull in Paris and Maria Cheng in London contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
[A]:
Experts scramble, but new virus vaccine may not come in time.